



Newron extends Senior Management team and strengthens commitment to ESG

Milan, Italy, July 1, 2022 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it is extending its Senior Management team through the appointment of Filippo Moriggia to the newly created position of Vice President of Operations, effective today. Filippo joined Newron in November 2016 as IT Director and became Director of Operations in January 2022.

Furthermore, as part of a renewed commitment to Environment, Social and Governance (ESG) within its corporate strategy, Newron is undertaking a comprehensive assessment of key ESG topics that are material to the company and its stakeholders. Based on the findings of this assessment, Newron will subsequently develop relevant and measurable targets for its ESG activities and track progress to achieving these targets over time.

To ensure appropriate oversight of this bolstered ESG commitment, Newron’s Board of Directors has established an ESG Committee as per today. On an operational level, ESG implementation and reporting will be spearheaded by Filippo Moriggia.

Stefan Weber, Newron’s Chief Executive Officer, commented: *“We warmly welcome Filippo to the Senior Management team, and we are proud to have established for the first time an ESG committee on Board level, which underlines our renewed commitment to ESG. We look forward to conducting a thorough, company-wide assessment with our stakeholders to develop and define our ESG goals. Following which we will aim to publish our ESG strategy and targets by the end of 2022 and begin our annual ESG reporting in March 2023 with our next Annual Report”.*

About Newron

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron’s Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with symptoms of schizophrenia. For more information, please visit: www.newron.com

For more information, please contact:

Newron

Stefan Weber – CEO
+39 02 6103 46 26, pr@newron.com

UK/Europe

Simon Conway / Ciara Martin, FTI Consulting
+44 20 3727 1000, SCnewron@fticonsulting.com

Switzerland

Valentin Handschin, IRF
+41 43 244 81 54, handschin@irf-reputation.ch

**Germany/Europe**

Anne Hennecke, Caroline Bergmann, MC Services
+49 211 52925222, anne.hennecke@mc-services.eu

USA

Paul Sagan, LaVoieHealthScience
+1 617 374 8800, Ext. 112, psagan@lavoiehealthscience.com

Important Notices

This document contains forward-looking statements, including (without limitation) about (1) Newron's ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron's financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as "will", "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "target", and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections, and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.